RELMADA THERAPEUTICS, INC. (RLMD) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Sep-30-21	Jun-30-21	Mar-31-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q
Operating expenses:
Research and development						80.3	57.5	45.5
General and administrative						32.2	29.5	27.8
Total operating expenses						112.4	87.0	73.3
Loss from operations						-112.4	-87.0	-73.3

Other (expenses) income:
Interest/investment income, net						1.3	1.3	1.8
Realized (loss) gain on short-term investments						-0.4	-0.2	-0.1

Unrealized (loss) gain on short-term investments
Total other income						2.1	2.3	4.1
Net loss						-112.1	-86.4	-71.0

Loss per common share – basic (in Dollars per share)						($6.63)	($5.24)	($4.41)

Weighted average number of common shares outstanding – basic (in Shares)						16.7	16.3	15.9